Drug-induced activation of TLR9 was proven to moderately improve immunogenic tumor sensitivity and augment innate immunity to promote tumor regression, thus indicating plausible potential synergetic effects between TLR9 agonist and PD-1 inhibitors (37). Here, TLR9 is linked to neoplasm.